Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease
Recruiting · NCT05509387 · Interventional (participants receive a specific treatment) · Lead sponsor: Baycrest
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct current stimulation (tDCS) has the potential to be a clinically effective therapy for both AD and FTD. The challenge now is to specify the parameters and conditions under which tDCS is most effective to transition from the laboratory to clinical medicine. tDCS studies typically report significant group effects despite the variability demonstrated among participants, with some showing clear, meaningful improvement, while others only show statistical improvement or none at all. These variable results may be related to the conventional stimulation intensity level of 2mA. The investigators predict that administering tDCS at 4.0 mA, a more significant number of participants would show a meaningful response, and those who improve at 2mA may improve even more from 4.0mA due to having a larger electric field produced. The investigators aim to test this hypothesis in people with Alzheimer's Disease.
Who can take part
Inclusion criteria
- Mild to Moderate AD
- Score between 18 and 25 on the MoCA
- Score on the Cambridge Naming Task during the pre-assessment
Exclusion criteria
- No history of stroke or TBI
- No shunts or metal in the body
- No history of significant heart disease, alcoholism and drug use
Where it is running
1 location listed.
- Baycrest Health Sciences - Toronto, Ontario, Canada